Full-Time

Fixed-Term

Manufacturing Associate I, Drug Substance

Confirmed live in the last 24 hours

Moderna

Moderna

5,001-10,000 employees

Develops mRNA-based medicines for health

Biotechnology
Healthcare

Entry, Junior

Oxford, UK

This position is site-based, requiring full-time presence at Moderna’s site.

Category
Healthcare Administration & Support
Medical, Clinical & Veterinary
Requirements
  • 1+ years of experience in a GMP manufacturing environment
  • A university degree with a specialization in Pharmaceutical production technology or equivalent
  • Experience with filtration and chromatography, and cold chain management a plus
  • Experience in audit / inspection preparation, understanding Health authority and regulatory guidelines
  • Ability to collaborate fluidly with peers, leadership and cross-functional support groups required
  • Excellent written, oral communication, and organizational skills required
  • Ability to maintain attention to detail while executing multiple tasks with minimal supervision
  • Demonstrated commitment to Moderna's values of Bold, Collaborative, Curious, and Relentless, embodying these values in the workplace
Responsibilities
  • Ensuring safety and compliance with Moderna’s procedures and health regulations.
  • Performing and documenting routine manufacturing operations.
  • Participating in quality assurance activities and continuous improvement initiatives.
  • Collaborating effectively within a dynamic, cross-functional team environment.
  • Maintaining and troubleshooting equipment and digital tools.
  • Engaging in root cause analysis and corrective action plans.
  • Supporting the team in achieving operational excellence and meeting KPIs.

Moderna focuses on developing medicines using messenger RNA (mRNA), which is a crucial component in how cells produce proteins necessary for various biological functions. Their approach involves creating a new class of medicines that utilize mRNA to instruct cells to produce specific proteins, potentially leading to significant advancements in treatment options for patients. Unlike traditional pharmaceuticals, which often rely on chemical compounds, Moderna's mRNA-based therapies aim to enhance the discovery, development, and manufacturing processes of medicines. The company's goal is to harness the power of mRNA to improve patient outcomes and create effective treatments for a range of diseases.

Company Stage

IPO

Total Funding

$5.9B

Headquarters

Cambridge, Massachusetts

Founded

2010

Growth & Insights
Headcount

6 month growth

4%

1 year growth

16%

2 year growth

55%
Simplify Jobs

Simplify's Take

What believers are saying

  • mRNA technology is expanding into personalized cancer vaccines, revolutionizing treatment.
  • Recent advancements in lipid nanoparticle delivery enhance mRNA vaccine efficacy.
  • Global mRNA vaccine market projected to grow significantly, boosting Moderna's prospects.

What critics are saying

  • Potential exclusion from Nasdaq 100 could impact investor perception and liquidity.
  • Bypassing safety steps in Australia may raise regulatory scrutiny.
  • Geopolitical tensions in China pose operational and financial risks for Moderna.

What makes Moderna unique

  • Moderna is pioneering mRNA technology for a new class of medicines.
  • The company has developed one of the earliest and most effective COVID-19 vaccines.
  • Moderna's mRNA platform enables rapid development of vaccines for various diseases.

Help us improve and share your feedback! Did you find this helpful?